ArticleResearch square2026

Direct Coronary Vascular and Lipidomic Remodeling by Low-Dose GLP-1 Agonist Therapy in Cardiometabolic HFpEF.

David Lefer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.